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Background: End-stage renal disease (ESRD) patients treated with renal replacement therapy (RRT) have premature
immunologically aged T cells which may underlie uremia-associated immune dysfunction. The aim of this study
was to investigate whether uremia was able to induce premature ageing of the T cell compartment. For this
purpose, we examined the degree of premature immunological T cell ageing by examining the T cell differentiation
status, thymic output via T cell receptor excision circle (TREC) content and proliferative history via relative telomere
length in ESRD patients not on RRT.
Results: Compared to healthy controls, these patients already had a lower TREC content and an increased T cell
differentiation accompanied by shorter telomeres. RRT was able to enhance CD8+ T cell differentiation and to
reduce CD8+ T cell telomere length in young dialysis patients. An increased differentiation status of memory CD4+
T cells was also noted in young dialysis patients.
Conclusion: Based on these results we can conclude that uremia already causes premature immunological ageing
of the T cell system and RRT further increases immunological ageing of the CD8+ T cell compartment in particular
in young ESRD patients.
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Loss of renal function is related to impaired function of
the T cell-mediated immune system. Changes in T cell
subsets and function may underlie this effect [1,2]. Clin-
ical consequences of this T cell-mediated immune dys-
function are a reduced efficiency of vaccination [3,4], an
enhanced susceptibility for infectious diseases [5] and an
enchanced risk for developing auto-immune diseases
and tumors [6].
T cells leave the thymus as naïve cells. Upon encoun-
tering of antigens presented by antigen presenting cells,
naive T cells will differentiate into effector T cells and
eventually only a fraction of these will develop into
memory T cells. The expression of (chemokine C-C
motif receptor 7) CCR7 and CD45RO can be used to
distinguish between the different T cell subsets, i.e. naïve
(CD45RO-CCR7+), central memory (CM, CD45RO+* Correspondence: r.meijers@erasmusmc.nl
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reproduction in any medium, provided the orCCR7+, able to home into lymphoid tissues), effector
memory (EM, CD45RO+CCR7-, exerting direct effector
functions) and the more terminally differentiated ef-
fector memory CD45RA+ (EMRA, CD45RO-CCR7-, high
in effector function) subset [2,7,8]. In addition, the loss
of cell surface CD28 expression identifies more differen-
tiated T cells [9].
During ageing in healthy individuals, the thymic out-
put of new naïve T cells reduces due to the involution of
the thymus. Absolute T cell numbers are largely con-
served by homeostatic proliferation of both naïve and
memory T cells but eventually this leads to a reduced
population of naïve T cells and a relatively preserved
population of memory T cells [10]. Elderly individuals
have a marked decrease in naïve T cells,, a decline in
CD4/CD8 ratio and a relative increase in the number of
differentiated memory T cells lacking CD28 [10-12].
The thymic output of new naïve T cells can be deter-
mined by measuring the T cell receptor excision circles
(TRECs)[13]. These TRECs are small circular DNA epi-
somes that are formed during rearrangement of the TLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the thymus. These TRECs are not replicated and there-
fore diluted with every cell division. Another hallmark of
ageing is the reduction in telomere length [14,15]. Telo-
meres are small DNA sequences located at the end of a
chromosome and with increasing age they become
shorter due to the inability of telomerase to elongate
these DNA sequences upon division. Together, TREC
content and telomere length reflect the thymic output
and replicative history of T cells and may provide a valu-
able tool to estimate the immunological age of the T
cells within an individual.
Using these ageing parameters, the T cell system of a
dialysis patient shows severe T cell ageing and resembles
that of a 20–30 year older healthy individual [1]. This
premature ageing of the T cell system probably underlies
the uremia-associated immune defect in dialysis patients.
However, it is not known whether the T cell system of
ESRD patients not on renal replacement therapy (RRT)
shows a similar degree of immunological ageing and to
what extent this is influenced by RRT.
In this cross-sectional study, we have analyzed the T
cell ageing parameters in ESRD patients who are not on
RRT and compared this to healthy individuals on one
hand, and patients treated with RRT (i.e. hemodialysis or
peritoneal dialysis) on the other hand.
Results
T cell ageing parameters in hemodialysis and peritoneal
dialysis patients
Initially, T cell numbers and ageing parameters of ESRD
patients treated with hemodialysis were compared to
peritoneal dialysis patients but no statistically significant
differences were observed. Therefore, the data of these
two RRT groups were combined for comparison with
the data of ESRD patients not on RRT (non-RRT group).
The clinical and demographic characteristics of patients
and healthy controls are shown in Table 1. Compared to
the old ESRD patient group, the young patients showed
a different distribution of underlying kidney diseases
(less frequently hypertensive nephropathy and more fre-
quently reflux nephropathy). Moreover, the young RRT
group had a longer history of dialysis treatment than the
old RRT group. However, type of underlying kidney dis-
ease and dialysis vintage were not significantly associated
with any of the ageing parameters measured.
CD4+ T cell differentiation is increased in ESRD patients
but marginally affected by RRT
The young and old non-RRT groups had significant
lower numbers of CD4+ T cells when compared to age-
matched Healthy Controls (HC). In the young non-
RRT group, a lower absolute number of memory T cells
and comparable numbers of naïve T cells were observedwhen compared to that of age-matched HC. Especially
in the old non-RRT group, the CD4+ T cells were
shifted towards the memory phenotype with significant
less naïve T cells when compared to age-matched HC
(Figure 1A). The CD4+ memory compartment of the
non-RRT group contained significantly (p < 0.01) lower
numbers of central memory T cells, resulting in a relative
increase of more differentiated effector-memory T cells
when compared tot that of age-matched HC (Figure 1B).
No differences were observed if RRT patients were com-
pared to age-matched non-RRT patients, with respect to
the composition of the total CD4+ T cell population
(Figure 1A) and differentiation of memory CD4+ T cells
(Figure 1B).
Elderly, but not young, non-RRT patients had a more
differentiated memory phenotype when compared to
that of age-matched HC (Figure 1C) based on the per-
centage of CD28null memory T cells (7.69 ± 1.46% versus
3.83 ± 0.49%, p < 0.05). RRT only resulted in a significant
(p < 0.05) higher percentage of CD4+CD28null memory
T cells in the young patient group (Figure 1C).
CD8+ T cell differentiation is increased and significantly
different in the young RRT patients
Compared to the CD4+ T cell compartment, the number
and differentiation of circulating CD8+ T cells was more
affected in non-RRT patients. On average, absolute
numbers of CD8+ T cells were lower compared to age-
matched HC which was largely attributable to a signifi-
cant decrease in memory T cells in young non-RRT
patients, and decreased naïve T cell numbers in the old
non-RRT group (Figure 2A). Comparing old non-RRT
patients to age-matched RRT patients revealed a slight
but significantly (p < 0.05) decreased number of naïve
and memory T cells (Figure 2A).
The CD8+ memory T cell compartment of the young
and old non-RRT groups consisted of significantly
(p < 0.01) less CM when compared to age-matched HC,
resulting in relatively more differentiated CD8+ T cells
with a EM/EMRA phenotype (Figure 2B). The influence
of RRT was only observed within the young RRT group.
These younger patients receiving RRT showed an
increased differentiation of the memory CD8+ T cell
compartment, reflected by an increase in EMRA T cell
numbers (p < 0.01, Figure 2B) compared to non-RRT
patients. This finding was in accordance with the
increased percentage of memory CD8+ T cells lacking
CD28 on their cell surface as compared to the group of
young non-RRT patients (p < 0.05, Figure 2C).
Thymic output of T cells and relative telomere length of
CD4+ and CD8+ T cells
In young and old non-RRT patients a lower thymic T
cell output was shown by the significant lower TREC
Table 1 Study population characteristics
End-stage renal disease patients not
receiving renal replacement therapy
End-stage renal disease patients
receiving renal replacement therapy
Healthy controls
Group Young Old Young Old Young Old
Number of individuals 22 33 49 49 55 65
Age in Years 33.5 ± 9.6* 64.4 ± 6.3* 35.7 ± 8.5* 63.1 ± 8.7* 38.4 ± 7.9* 63.5 ± 7.5*
Male 77.3% 60.6% 55.1% 71.4% 49.1% 38.5%
CMV positive 54.5% 51.2% 59.2% 53.1% 50.9% 49.2%
Hemodialysis 25 32
Peritoneal dialysis 24 17
Duration of RRT (years) 4.30 (0.1 - 22)** 2.76 (0.2 - 18)**
Underlying kidney disease
- Hypertensive nephropathy 13.6% 27.2% 20.8% 30.6%
- Primary glomerulopathy 31.8% 18.2% 18.8% 18.4%
- Diabetic nephropathy 0% 21.2% 2.1% 8.2%
- Polycystic kidney disease 9.1% 9.0% 0% 2.0%
- Reflux nephropathy 18.2% 3.0% 14.6% 4.1%
- Other 9.1% 15.2% 20.9% 8.2%
- Unknown 18.2% 6.0% 22.9% 28.6%
* Data are given in means with standard deviation.
** Data are given in means with range.
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(Figure 3A, p < 0.05) for comparison of the two lines.
Using linear regression analysis for both HC as well as
non-RRT patients, an average immunological age for a
non-RRT patient with a calendar age of 40 years was
estimated. For this purpose, the value for thymic output
(deltaCt, TREC content) of this 40 year old patient was
calculated using the formula for the regression line of
non-RRT patients. This value was then plotted in the
formula for the regression line of HC and resulted in an
average calendar age of 46.6 years. The immunological
age of the patient’s T cells using thymic output was thus
increased with approximately 7 years (Figure 3A), lines
indicate the discrepancy between calendar ages of a non-
RRT patient and a HC (i.e. the immunological age of the
non-RRT patient), respectively. However, the TREC con-
tent was equally low for non-RRT and RRT patients
(Figure 3B).
The relative telomere length (RTL) of CD4+
(Figure 4A) as well as CD8+ T cells (Figure 4C)
decreased in both HC and non-RRT patients with in-
creasing age, although these patients had or tendet to
have shorter telomeres within both CD4+ T cells
(p < 0.05, Figure 4A) and CD8+ T cells (P = 0.07,
Figure 4C) when compared to age-matched HC. Using
regression analysis for these ageing parameters, as
described above, the immunological age of a 40-year old
non-RRT patient amounted to approximately 60 years.
A significant (p < 0.05) lower RTL for CD8+
(11.17 ± 0.74% versus 15.15 ± 1.73%, Figure 4D), wasfound in the young RRT group when compared to the
non-RRT group. No differences in RTL were observed
for the CD4+ T cells between RRT and non-RRT groups
(Figure 4B).
Discussion
The results of this study show that based on several im-
munological parameters, ESRD without RRT is asso-
ciated with premature immunological ageing of the T
cell system. The added effect of RRT on this
phenomenon is remarkably small and was predomin-
antly limited to the CD8+ T cell compartment in young
ESRD patients.
Most studies on the immune system of patients with
renal failure have been performed in chronic ESRD
patients treated with RRT, mainly hemodialysis. Lym-
phopenia and signs of T cell activation have been
reported in a lot of the studies [16,17]. In-depth analysis
of T cell subsets showed that lymphopenia is particularly
prominent in the naïve T cell subset which showed a
progressive decline in numbers as the stage of chronic
kidney disease increased [2,18]. In a recent study, we
showed that decreased numbers of naïve T cells in
hemodialysis patients is related to decreased thymic out-
put of naïve T cells with increased but insufficient
homeostatic proliferation in the periphery [19]. Memory
T cells were in general more differentiated probably due
to increased proliferation, given the decrease in relative
telomere length. Similar findings were now observed
for ESRD patients not on dialysis, indicating that loss
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Figure 1 CD4+ T cell phenotype and differentiation status.
Using a whole blood staining, the phenotype and differentiation
status of CD4+ T cells were determined in HC and ESRD patients not
on RRT or receiving RRT. The absolute number of CD4+ T cells of
young (age: <50 years) and old (age: ≥50 years) HC and these ESRD
patients was dissected into a naïve (closed bars) and memory (open
bars) compartment (A). Next, the composition of the memory
compartment (CM in black and EM in grey bars) of CD4+ T cells is
given for young and old HC and ESRD patients on RRT or not (B). In
addition, we also determined the percentage memory CD4+ T cells
lacking CD28 (i.e. CD28null) on their cell surface as another marker
for T cell differentiation for HC (grey bars) and ESRD patients not on
RRT (white bars) or receiving RRT (black bars) (C). Bars represent the
means + SEM and statistically significant differences between the
groups are shown (one symbol: p < 0.05, two symbols: p < 0.01, three
symbols: p < 0.001).
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Figure 2 CD8+ T cell phenotype and differentiation status.
Using a whole blood staining, the phenotype and differentiation
status of CD8+ T cells were determined in HC and ESRD patients not
on RRT or receiving RRT. The absolute number of CD8+ T cells of
young (age: <50 years) and old (age: ≥50 years) HC and these ESRD
patients was dissected into a naïve (closed bars) and memory (open
bars) compartment (A). Next, the composition of the memory
compartment (CM in black, EM in grey and EMRA in white bars) of
CD8+ T cells is given for young and old HC and ESRD patients on
RRT or not (B). In addition, we also determined the percentage
memory CD8+ T cells lacking CD28 (i.e. CD28null) on their cell
surface as another marker for T cell differentiation for HC (grey bars)
and ESRD patients not on RRT (white bars) or receiving RRT (black
bars) (C). Bars represent the means + SEM and statistically significant
differences between the groups are shown (one symbol: p < 0.05,
two symbols: p < 0.01, three symbols: p < 0.001).
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http://www.immunityageing.com/content/9/1/19of renal function is the most dominant factor for
decreased thymic output of naïve T cells and increased
differentiation/proliferation of memory T cells. In
healthy individuals these changes are observed in theelderly and therefore considered as a physiological
process of immunological ageing of the T cell system.
In comparison to the CD8+ T cells, the CD4+ T cell
system in healthy individuals remains relatively un-
affected by age until the seventh or eighth decade
[10,12,20-23]. However, patients with ESRD not on
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Figure 3 Quantification of the TREC content by quantitative
PCR. The threshold cycle (Ct) is the number of amplification cycles
needed to detect the TRECs and is a relative measure, inversely
related with the concentration of TRECs. Control for DNA input was
done by performing a quantitative PCR (qPCR) for albumin and the
difference between the Ct for TRECs and the Ct for albumin was
calculated (ΔCt). The ΔCt, indicative for TREC content, was
determined of HC (straight line) and ESRD patients not on RRT
(dotted line) and lines were compared using a linear regression
analysis (p < 0.05 for the difference between lines for ESRD patients
not on RRT and HC). The lines in (A) mark the discrepancy between
the calendar age (i.e. 40 years) of a non-RRT patient and the
immunological age, by extrapolation of the value for the deltaCT
(TREC content) to the HC regression line. In addition, Spearmans Rho
correlation coefficients (Rs) were calculated for HC and ESRD
patients not on RRT to determine the strength of the association
between TREC content (calculated as ΔCt) and age. Age is depicted
on the X-axis whereas on the Y-axis the ΔCt value for TREC content
is displayed. Next, the effect of RRT on the TREC content (B) was
analyzed by dissecting the ESRD patients into a young (<50 years)
and old (≥50 years) group and either not (white bars) or receiving
(black bars) RRT. Bars represent means + SEM.
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ageing (lower thymic output, shorter telomeres) of their
T cell system, approximately 10–20 years ahead of their
calendar age. The reasons for premature T cell ageing in
patients with chronic renal failure are not known but a
relative lack of the T cell growth factor IL-7 has been
documented and may be important [1,2]. In animalmodels it was clear that sudden loss of renal function
causes involution of the thymus and other lymphoid
organs confirming a direct relationship between kidney
function and lymphopoiesis [24]. Lymphopenia may trig-
ger increased homeostatic proliferative responses [25],
not only of the circulating naïve T cell compartment but
also of memory T cells thereby inducing differentiation
and loss of telomere length. However this concept is
hypothetical and has not been tested yet in ESRD
patients.
In general, immunological ageing of T cells (e.g.
increased numbers of CD28null T cells) has been asso-
ciated with decreased T cell immunity. Maintenance and
generation of a number of antibody responses seems
critically dependent on the presence of antigen-specific
CD4+ T cells [3,26]. Any major disturbances of the T cell
system will therefore affect the humoral immune re-
sponse as well. ESRD-related premature immunological
T cell ageing may therefore underlie the well-established
uremia-associated cellular and humoral immune defi-
ciency in ESRD patients [1].
In a previous study, it was shown that loss of naïve T
cells and increased memory T cell differentiation pro-
gresses with increasing stage of chronic kidney disease
but with little difference between ESRD patients with or
without RRT [2,18]. Also on the level of T cell chemo-
kine receptor expression, which is indicative for func-
tional capacities of T cells few differences were observed
between T cells of ESRD patient with or without RRT.
These findings are remarkable as most patients on dialy-
sis have little to no residual renal function and as such
are metabolically more affected than ESRD patient not
on dialysis. The results in this study are largely in ac-
cordance with these data and show that patients with
RRT do not have an altered thymic output of naïve T
cells and total numbers of naïve T cells. Summarizing
the present data, it appears that the maximum effect of
loss of renal function on the T cell immune system is
reached at the level of ESRD. Whether RRT prevents
further immunological ageing or not is difficult to assess
and cannot be inferred from our data.
However, the CD4+ and CD8+ memory T cells in
young dialysis patients showed more differentiation and
in the CD8+ T cells this was accompanied by a decrease
in RTL. Thus, particularly memory CD8+ T cells in
younger patients show a history of more proliferation
without the presence of decreased thymic output. This
finding indicates that in younger dialysis patients, on top
of ESRD-related immunological ageing, other factors
drive the proliferation of memory T cells. The dialysis
vintage of younger patients was on average higher than
the old group suggesting a role for duration of RRT and
loss of telomere length. However, we could not find an
independent statistically significant relation between
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Figure 4 Relative telomere length of CD4+ and CD8+ T cells. The relative telomere length (RTL) of the CD4+ (A) and CD8+ (C) T cells is
determined of HC (straight line) and ESRD patients not on RRT (dotted line) and lines were compared using a linear regression analysis i.e.
p < 0.05 and p= 0.07 when comparing the differences between HC and non-RRT patients with respect to CD4+ RTL and CD8+ RTL respectively.
The lines in A and C highlight the discrepancy between the calendar age (i.e. 40 years) of a non-RRT patient and the immunological age, by
extrapolation of the value for the CD4+ and CD8+ RTL to the HC regression line, respectively. In addition, Spearmans Rho correlation coefficients
(Rs) were calculated for HC and ESRD patients not on RRT to determine the strength of the association between RTL and age. Age is depicted on
the X-axis and the RTL on the Y-axis. The effect of RRT on the RTL of CD4+ (B) as well as CD8+ (D) T cells was analyzed by dissecting the ESRD
patients into a young (<50 years) and old (≥50 years) group and either not receiving RRT (white bars) or receiving RRT (black bars). Bars represent
means + SEM. Statistical differences between the groups are shown (* p < 0.05).
Meijers et al. Immunity & Ageing 2012, 9:19 Page 6 of 8
http://www.immunityageing.com/content/9/1/19duration of RRT and any of the immunological para-
meters measured. In addition, the type of underlying
kidney diseases was not related to any parameter of im-
munological ageing. Another possible scenario may be
that RRT actually improves homeostatic proliferation of
memory T cells in the young but not in the elderly
patients. However, this should result in a relative in-
crease in memory T cell numbers in the young RRT
patients compared to ESRD patients without RRT which
was not observed. The lack of such a finding would
argue against this explanation.
A limitation of the present study is the cross-sectional
design which may obscure subtle changes in immuno-
logical T cell ageing after patients with ESRD have
started RRT. However, the large number of patients
included in this study adds to the reliability of the
results.In conclusion, severe loss of renal function leading to
ESRD is a very potent inducer of premature immuno-
logical T cell ageing of both the CD4+ and CD8+ T cells.
Renal replacement therapy is associated with a small in-
crease of memory T cell ageing in patients <50 years of
age, particularly in the CD8+ T cell subset. Further re-
search is needed to establish the pathophysiology of
ESRD-related T cell ageing and whether this can be
reversed by e.g. interleukin-7 therapy [27,28] or kidney
transplantation.
Methods
Study population
ESRD patients were defined by a glomular filtration rate
(GFR) of ≤ 15 ml/min and were either not on RRT or
treated with hemodialysis or peritoneal dialysis. Patients
having an infection, malignancy, autoimmune disease or
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ous kidney transplantations) were excluded. Healthy
individuals were included as controls. They were
matched for age and cytomegalovirus (CMV) positivity,
as these are well-known factors affecting the compos-
ition of the T cell compartment [1,19]. The clinical and
demographic characteristics of the ESRD patients and
HC are shown in Table 1. All individuals included gave
informed consent and the local medical ethical commit-
tee approved the study (METC number: 2012–022). It
was conducted according to the principles of Declaration
of Helsinki and in compliance with International
Conference on Harmonization/Good Clinical Practice
regulations.
Differentiation status of circulating T cells
T cell phenotype and differentiation status was analyzed
as described previously [1,19]. Briefly, whole blood was
stained with AmCyan labeled anti-CD3 (BD Biosciences,
Erembodegem, Belgium) in combination with pacific
blue labeled anti-CD4 (BD) or allophycocyanin Cy7
(APC-Cy7) labeled anti-CD8 (BD) to identify CD4+ or
CD8+ T cells that are further dissected into four different
subsets based on the expression of CCR7 and CD45RO
using fluorescein isothiocyanate (FITC) labeled anti-
CCR7 (R&D systems, Uithoorn, The Netherlands) and
allophycocyanin (APC) labeled anti-CD45RO (BD).
Naive T cells are CCR7+ and CD45RO-, Central memory
(CM) cells are CCR7+ and CD45RO+, Effector memory
(EM) cells are CCR7- and CD45RO+ and EMRA cells
are CCR7- and CD45RO-.
T cell differentiation is associated with loss of CD28
expression on cell surface. Percentages of CD28- (or
CD28null) T cells within the T cell subsets were deter-
mined by staining with peridinin chlorophyll-Cy5.5
(PerCP-Cy5.5) labeled anti-CD28 (BD).
PBMC isolation
Peripheral blood mononuclear cells (PBMC) were iso-
lated from heparinized blood samples by Ficoll gradient
centrifugation. In hemodialyis patients, the blood sam-
ples were drawn before a hemodialysis session [1]. Two
million PBMC were snap-frozen for the TREC assay and
the rest of the PBMC were frozen in liquid nitrogen with
a minimum amount of 10 × 106 cells per vial for further
experiments.
DNA isolation and TREC assay
TREC content was assessed using the snap-frozen
PBMC. Briefly, DNA was isolated according to manufac-
turer’s instructions (Qiagen Isolation kit, Qiagen, Venlo,
the Netherlands). Subsequently, TREC content was
determined using quantitative PCR. For this purpose, a
combination of two primers and a hydrolysis probespecific for the so-called δREC(TCRD)-ψJα(TCRA)
TREC (sjTREC) were employed. TaqMan quantitative
PCR was performed on 50 ng DNA in a 25 μl reac-
tion mixture containing 700 nmol/l of each primer
5’-TCGTGAGAACGGTGAATGAAG-3’ and 5’-CCATGC
TGACACCTCTGGTT-3’, 150 nmol/l of hydrolysis probe
5’-(FAM)CACGGTGATGCATAGGCACCTGC-3’ (TAMRA),
and 12.5 μl 2× TaqMan Universal PCR Master Mix
(Applied Biosystems, Nieuwerkerk a/d IJssel, The
Netherlands). Quantification of the DNA amount in
each sample was performed using a quantitative PCR
of the single-copy albumin gene. All reactions were
performed in duplicate, unless a threshold cycle (Ct)
difference between replicates of >1.5 necessitated to
repeat the PCR experiment. ΔCt was calculated by
using the formula: Ct value TREC PCR – Ct value
albumin PCR [13].
Telomere length assay
Flow fluorescent in situ hybridization was performed to
determine the relative telomere length of CD4+ and CD8+
T cells. For this purpose, the frozen PBMC were
thawed and stained with either CD4-biotin (Beckman-
Coulter, BV, Woerden, The Netherlands) or CD8-biotin
(Biolegend, Europe BV, Uithoorn, the Netherlands) fol-
lowed by staining with streptavidin-Cy5 (Biolegend).
The PBMC were fixed and permeabilized (Invitrogen
Life Technologies, Bleiswijk, The Netherlands) before
the relative telomere length (RTL) was determined
using the telomere PNA-kit/FITC (Zebra Bioscience
BV, Enschede, The Netherlands). The sub cell line 1301
of CCRF-CEM, which is known to have long telomeres,
was used to calculate the relative telomere length (RTL)
of the CD4+ and CD8+ T cells [1,29].
Statistical analysis
Patients not on RRT were compared to healthy controls
on one hand and to patients receiving hemodialysis or
peritoneal dialysis on the other hand using the Mann–
Whitney test. For the TREC content and the RTL, a lin-
ear regression model was used to compare patients not
on RRT to healthy controls. In addition, Spearman Rho
correlation coefficients (Rs) were calculated to determine
the strength of the association between the different age-
ing parameters and age for HC as well as ESRD patients
not on RRT. All statistical tests were performed two-
sided and a p-value of <0.05, was considered significant.
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